Acute Ischemic Stroke Ais Pipeline Insight

DelveInsight’s, “Acute Ischemic Stroke (AIS) – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Acute Ischemic Stroke (AIS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Acute Ischemic Stroke (AIS) Understanding

Acute Ischemic Stroke (AIS): Overview

Acute Ischemic Stroke (AIS) results from a sudden cessation of adequate amounts of blood reaching parts of the brain. Ischemic strokes can be divided according to territory affected or mechanism. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, the more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain. Symptoms depend on severity of the stroke and location in the brain. Some people do not experience any symptoms and others experience only one. Symptoms may include: Paralysis on one side of the body, Change in alertness, Changes in hearing or taste, Problems swallowing, Dizziness or loss of balance, and Problems with eyesight. Treatment consists of one or a combination of two basic approaches to restore proper blood flow: 1) an injection of a clot-busting drug and 2) mechanical thrombectomy, a minimally-invasive procedure that physically removes clot from blocked arteries.


"Acute Ischemic Stroke (AIS) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Ischemic Stroke (AIS) pipeline landscape is provided which includes the disease overview and Acute Ischemic Stroke (AIS) treatment guidelines. The assessment part of the report embraces, in depth Acute Ischemic Stroke (AIS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke (AIS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Ischemic Stroke (AIS) R&D. The therapies under development are focused on novel approaches to treat/improve Acute Ischemic Stroke (AIS).

Acute Ischemic Stroke (AIS) Emerging Drugs Chapters

This segment of the Acute Ischemic Stroke (AIS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Acute Ischemic Stroke (AIS) Emerging Drugs


Nerinetide: NoNO

Nerinetide (formerly NA 1) is being developed by Arbor Vita Corporation (USA) and NoNO Inc. Nerinetide is an eicosapeptide that inhibits post-synaptic density protein 95 (PSD-95) signaling. It is believed to act as a neuroprotectant that promotes cell survival and disrupts toxic cell signals following damage to neurons. The drug is in Phase III stage of development for the treatment of patients with Acute Ischemic Stroke (AIS).


Pro-UK: Tasly Pharmaceutical

Recombinant human (rh) Pro-UK, is a novel type of thrombolytic, which preferentially activates plasminogen on the fibrin surface and induces fibrin-selective clot lysis. The drug is in Phase III clinical trials in Acute Ischemic Stroke (AIS).

Further product details are provided in the report……..

Acute Ischemic Stroke (AIS): Therapeutic Assessment

This segment of the report provides insights about the different Acute Ischemic Stroke (AIS) drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Acute Ischemic Stroke (AIS)

There are approx. 20+ key companies which are developing the therapies for Acute Ischemic Stroke (AIS). The companies which have their Acute Ischemic Stroke (AIS) drug candidates in the most advanced stage, i.e. Phase III include, NoNO.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Acute Ischemic Stroke (AIS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Ischemic Stroke (AIS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Ischemic Stroke (AIS) therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Ischemic Stroke (AIS) drugs.

Acute Ischemic Stroke (AIS) Report Insights

  • Acute Ischemic Stroke (AIS) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Acute Ischemic Stroke (AIS) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Acute Ischemic Stroke (AIS) drugs?
  • How many Acute Ischemic Stroke (AIS) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Ischemic Stroke (AIS)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Ischemic Stroke (AIS) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Ischemic Stroke (AIS) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Acute Ischemic Stroke (AIS): Overview

  • Causes
  • Mechanism of Action 
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type 

Acute Ischemic Stroke (AIS) – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Acute Ischemic Stroke (AIS) companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Acute Ischemic Stroke (AIS) Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III) 

  • Comparative Analysis

Nerinetide: NoNO

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Mid Stage Products (Phase II) 

  • Comparative Analysis

SP-8203: Shin Poong Pharmaceutical

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Early stage products (Phase I/II)

  • Comparative Analysis

JTR 161: Teijin Pharma Limited

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Acute Ischemic Stroke (AIS) Key Companies

Acute Ischemic Stroke (AIS) Key Products

Acute Ischemic Stroke (AIS)- Unmet Needs

Acute Ischemic Stroke (AIS)- Market Drivers and Barriers

Acute Ischemic Stroke (AIS)- Future Perspectives and Conclusion

Acute Ischemic Stroke (AIS) Analyst Views

Acute Ischemic Stroke (AIS) Key Companies

Appendix

List of Table

Table 1: Total Products for Acute Ischemic Stroke (AIS)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Acute Ischemic Stroke (AIS)

Figure 2: Late Stage Products 

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products      


• Tasly Pharmaceutical

• AstraZeneca

• Guangzhou Recomgen Biotech

• Supergene

• Healios

• Abbvie

• DiaMedica Therapeutics

• Jeil Pharmaceutical

• Lumosa Therapeutics

• Pharmazz

• Teijin Pharma Limited

• Acticor Biotech

• aptaTargets

• Meridigen Biotech

• DiaMedica therapeutics

• NoNO Inc

• Daiichi Sankyo Company

• Genentech

• Shin Poong Pharmaceutical

  • Tags:
  • Acute Ischemic Stroke (AIS) Pipelin...
  • Acute Ischemic Stroke (AIS) clinic...
  • Acute Ischemic Stroke (AIS) compan...
  • Acute Ischemic Stroke (AIS) drugs
  • Acute Ischemic Stroke (AIS) therap...
  • Acute Ischemic Stroke (AIS) treatm...
  • Acute Ischemic Stroke (AIS) pipeli...
  • Acute Ischemic Stroke (AIS) pipeli...

Forward to Friend

Need A Quote